J J Eron

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study
    Joseph J Eron
    Infectious Diseases Division, School of Medicine, University of North Carolina, Chapel Hill, NC 27599 7215, USA
    J Infect Dis 207:740-8. 2013
  2. ncbi request reprint Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection
    J J Eron
    General Clinical Research Center, Infectious Disease Division, University of North Carolina, Chapel Hill 27599 7030, USA
    AIDS 14:671-81. 2000
  3. ncbi request reprint Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation
    Joseph J Eron
    AIDS Clinical Research Unit, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Acquir Immune Defic Syndr 37:1581-3. 2004
  4. ncbi request reprint Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial
    Joseph J Eron
    Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Infect Dis 189:265-72. 2004
  5. ncbi request reprint HIV-1 protease inhibitors
    J J Eron
    Infectious Diseases Division, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7030, USA
    Clin Infect Dis 30:S160-70. 2000
  6. doi request reprint Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions
    Joseph J Eron
    Department of Internal Medicine, University of North Carolina School of Medicine, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    J Infect Dis 197:S261-71. 2008
  7. pmc Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy
    Joseph J Eron
    Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, 130 Mason Farm Rd, Bio Informatics Building CB No 7215, Chapel Hill, NC 27599 7215, USA
    Antimicrob Agents Chemother 53:2335-41. 2009
  8. ncbi request reprint The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    J J Eron
    Department of Medicine, Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 181:1622-8. 2000
  9. ncbi request reprint Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
    R L Murphy
    Division of Infectious Diseases, Northwestern University Medical School, Illinois, Chicago, IL 60611, USA
    J Infect Dis 179:808-16. 1999
  10. ncbi request reprint ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
    R L Murphy
    Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    AIDS 15:F1-9. 2001

Research Grants

Detail Information

Publications102 found, 100 shown here

  1. pmc Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study
    Joseph J Eron
    Infectious Diseases Division, School of Medicine, University of North Carolina, Chapel Hill, NC 27599 7215, USA
    J Infect Dis 207:740-8. 2013
    ..This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance...
  2. ncbi request reprint Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection
    J J Eron
    General Clinical Research Center, Infectious Disease Division, University of North Carolina, Chapel Hill 27599 7030, USA
    AIDS 14:671-81. 2000
    ....
  3. ncbi request reprint Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation
    Joseph J Eron
    AIDS Clinical Research Unit, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    J Acquir Immune Defic Syndr 37:1581-3. 2004
    ..Nucleoside analogue reverse transcriptase inhibitors may have continued ARV activity despite long durations of partially suppressive therapy and the presence of resistant HIV-1...
  4. ncbi request reprint Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial
    Joseph J Eron
    Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Infect Dis 189:265-72. 2004
    ..Genotypic resistance testing of 4 patients with HIV RNA levels >400 copies/mL between weeks 24 and 48 demonstrated no protease inhibitor-resistance mutations...
  5. ncbi request reprint HIV-1 protease inhibitors
    J J Eron
    Infectious Diseases Division, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7030, USA
    Clin Infect Dis 30:S160-70. 2000
    ....
  6. doi request reprint Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions
    Joseph J Eron
    Department of Internal Medicine, University of North Carolina School of Medicine, 130 Mason Farm Road, Chapel Hill, NC 27599, USA
    J Infect Dis 197:S261-71. 2008
    ..Structured treatment interruptions to reduce drug exposure and toxicity should not be used outside well-controlled research studies, since this practice has been associated with increased rates of death and disease progression...
  7. pmc Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy
    Joseph J Eron
    Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, 130 Mason Farm Rd, Bio Informatics Building CB No 7215, Chapel Hill, NC 27599 7215, USA
    Antimicrob Agents Chemother 53:2335-41. 2009
    ..The IQ improved correlation in analyses of all arms where a greater range of virologic responses was observed...
  8. ncbi request reprint The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850)
    J J Eron
    Department of Medicine, Infectious Diseases, University of North Carolina, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 181:1622-8. 2000
    ..Persistent replication of HIV in the genital tract may have implications for the selection of resistant virus and sexual transmission of HIV-1...
  9. ncbi request reprint Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team
    R L Murphy
    Division of Infectious Diseases, Northwestern University Medical School, Illinois, Chicago, IL 60611, USA
    J Infect Dis 179:808-16. 1999
    ..04 log10 copies/mL, and 17 (63%) of 27 evaluable subjects had <500 HIV RNA copies/mL. Treatment with amprenavir, zidovudine, and lamivudine together reduced the levels of HIV RNA significantly more than did amprenavir monotherapy...
  10. ncbi request reprint ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results
    R L Murphy
    Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    AIDS 15:F1-9. 2001
    ..The activity and durable suppression of HIV-1 observed in this study is probably attributable to the observed tolerability profile and the achievement of high ABT-378 plasma concentrations...
  11. ncbi request reprint Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
    R M Gulick
    Department of Medicine, New York University School of Medicine, New York, USA
    JAMA 280:35-41. 1998
    ..Combination antiretroviral therapy can markedly suppress human immunodeficiency virus (HIV) replication but the duration of HIV suppression varies among patients...
  12. ncbi request reprint Genotypic resistance and the treatment of HIV-1 infection in Espírito Santo, Brazil
    C D Pilcher
    Division of Infectious Diseases, Department of Medicine, University of North Carolina Chapel Hill, Chapel Hill, NC 27599 7030, USA
    J Infect Dis 179:1259-63. 1999
    ....
  13. ncbi request reprint A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir
    J J Eron
    University of North Carolina at Chapel Hill, 27599 7030, USA
    J Acquir Immune Defic Syndr 26:458-61. 2001
    ..The protease I50V mutation characteristic of APV resistance was not observed, although other key PI mutations were selected in 4 patients failing therapy, 2 of whom had PI resistance at baseline...
  14. ncbi request reprint Oral manifestations of HIV in a southeast USA population
    L L Patton
    Department of Dental Ecology, School of Dentistry, University of North Carolina, Chapel Hill 27599 7450, USA
    Oral Dis 4:164-9. 1998
    ..Examine variations in oral manifestations of HIV by gender, race, risk behaviors, substance use and immune status in a previously unstudied population in the southeast region of the USA...
  15. doi request reprint Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 300:555-70. 2008
    ....
  16. ncbi request reprint Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial
    Scott M Hammer
    Division of Infectious Diseases, Department of Medicien, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 288:169-80. 2002
    ..Management of antiretroviral treatment failure in patients receiving protease inhibitor (PI)-containing regimens is a therapeutic challenge...
  17. ncbi request reprint The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir
    Amanda H Corbett
    Schools of Pharmacy and Medicine, University of North Carolina Center for AIDS Research, University of North Carolina at Chapel Hill, 27599, USA
    J Acquir Immune Defic Syndr 36:921-8. 2004
    ..These data suggest that amprenavir/saquinavir/ritonavir may be a viable salvage regimen in heavily PI-experienced individuals. New formulations of amprenavir and saquinavir may simplify this regimen...
  18. ncbi request reprint Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men
    Naumann I Chaudry
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA
    Clin Infect Dis 35:760-2. 2002
    ..The majority of these concentrations were greater than the plasma protein-corrected 50% inhibitory concentration for wild-type human immunodeficiency virus type 1...
  19. doi request reprint Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
    Joseph J Eron
    University of North Carolina School of Medicine, Chapel Hill, NC, USA
    Lancet 375:396-407. 2010
    ..We compared substitution of raltegravir for lopinavir-ritonavir with continuation of lopinavir-ritonavir in HIV-infected patients with stable viral suppression on lopinavir-ritonavir-based combination therapy...
  20. ncbi request reprint Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Constance A Benson
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
    J Infect Dis 185:599-607. 2002
    ..Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events...
  21. pmc Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001-2007
    Chanelle J Howe
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina 27599 7435, USA
    AIDS Res Hum Retroviruses 26:875-81. 2010
    ..The UNC CFAR clinical cohort has ample enrollment with retention and visit attendance modestly influenced by factors such as disease severity...
  22. ncbi request reprint Frequent detection of acute primary HIV infection in men in Malawi
    Christopher D Pilcher
    Departments of Medicine and Epidemiology at the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS 18:517-24. 2004
    ..Acute (antibody-negative) HIV infection is associated with high transmission potential but is rarely recognized...
  23. ncbi request reprint A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease
    Margaret A Fischl
    Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
    J Infect Dis 188:625-34. 2003
    ..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity...
  24. ncbi request reprint Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva
    D C Shugars
    School of Dentistry, University of North Carolina at Chapel Hill, 27599 7450, USA
    J Dent Res 80:414-20. 2001
    ..Morphological characterization of cell pellets identified lymphocytes as a likely HIV-1 source. These collective findings are consistent with an oral HIV-1 reservoir in selected individuals...
  25. ncbi request reprint Sensitive method for the detection of infectious HIV in semen of seropositive individuals
    P L Vernazza
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    J Virol Methods 56:33-40. 1996
    ..It is concluded that the method is highly sensitive for the detection of HIV from semen. However, the recovery rate of infectious cell-free virus in seminal fluid from clinical samples is infrequent...
  26. ncbi request reprint Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group
    M S Cohen
    Department of Medicine, University of North Carolina, Chapel Hill 27599 7030, USA
    Lancet 349:1868-73. 1997
    ..We investigated the hypothesis that STDs increase the likelihood of transmission of HIV-1 through increased concentration of the virus in semen...
  27. ncbi request reprint Advanced immunosuppression at entry to HIV care in the southeastern United States and associated risk factors
    Cynthia L Gay
    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS 20:775-8. 2006
    ..Male sex was an independent predictor in multivariable analysis. These results indicate an urgent need to increase HIV testing for earlier diagnosis in the southeastern USA...
  28. ncbi request reprint Envelope diversity, coreceptor usage and syncytium-inducing phenotype of HIV-1 variants in saliva and blood during primary infection
    Stephanie A Freel
    School of Dentistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    AIDS 17:2025-33. 2003
    ....
  29. pmc Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1
    Kimberly Ritola
    University of North Carolina at Chapel Hill, 22 062 Lineberger Cancer Center, CB 7295, Chapel Hill, NC 27599 7295, USA
    J Virol 78:11208-18. 2004
    ..Alternatively, the inefficient transfer of a multiply infected cell could account for both the low probability of transmission and the transfer of multiple variants...
  30. pmc HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays
    Sonia Napravnik
    Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
    J Clin Virol 47:18-22. 2010
    ..Amplification based HIV-1 viral load and genotypic resistance assays are expensive, technologically complex and may be difficult to implement in resource limited settings. Inexpensive, simpler assays are urgently needed...
  31. ncbi request reprint HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health
    C D Pilcher
    School of Medicine, University of North Carolina at Chapel Hill, 27599-7030, USA
    AIDS 15:837-45. 2001
    ..Antiretroviral therapy is unlikely to limit initial virus spread to most tissue compartments, but may control genital tract shedding and central nervous system expansion in primary infection...
  32. ncbi request reprint Alternative strategies for anti-HIV treatment
    J J Eron
    Infectious Diseases Division, 547 Burnett Womack, CB 7030, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7030, USA
    AIDS 15:S161-9. 2001
    ..Strategies to enhance immune control and either discontinue or decrease the need for prolonged HAART are under study. The promising preliminary results in very early PHI are in contrast with the minor successes in chronic infection...
  33. ncbi request reprint The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration
    I F Hoffman
    University of North Carolina, Division of Infectious Diseases, Chapel Hill, USA
    AIDS 13:487-94. 1999
    ..This study was undertaken to determine the relative effect of malaria infection on HIV concentration in blood plasma, and prospectively to monitor viral concentrations after antimalarial therapy...
  34. ncbi request reprint Substance abuse and symptoms of mental illness among HIV-positive persons in the Southeast
    Kathryn Whetten
    Department of Public Policy, Duke University, Durham, NC, USA
    South Med J 98:9-14. 2005
    ..Mental illness and substance abuse have been consistently associated with poor HIV-medication adherence and other negative health outcomes...
  35. doi request reprint Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
    Nancy M Archin
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    AIDS 22:1131-5. 2008
    ..Valproic acid and intensified antiretroviral therapy may deplete resting CD4+ T-cell HIV infection. We tested the ability of valproic acid to deplete resting CD4+ T-cell infection in patients receiving standard antiretroviral therapy...
  36. ncbi request reprint Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV
    Joseph J Eron
    Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Infect Dis 189:1075-83. 2004
    ..43 to -0.05 log(10) copies/mL) for the lowest dose to -1.96 log(10) copies/mL (95% CI, -2.02 to -1.37 copies/mL) for the highest dose. These results indicate that T-1249 is a potent new therapeutic agent for HIV-1 infection...
  37. pmc Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials
    K H Moore
    Glaxo Wellcome Inc, Research Triangle Park, University of North Carolina at Chapel Hill, Chapel Hill, Durham, North Carolina 27709, USA
    Antimicrob Agents Chemother 43:3025-9. 1999
    ..However, as only three patients had an estimated creatinine clearance of <60 ml/min, dosage adjustments for patients with impaired renal function should not be determined based on the population parameters derived in this analysis...
  38. ncbi request reprint Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy
    L L Patton
    University of North Carolina, Department of Dental Ecology, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 89:299-304. 2000
    ..The purpose of this study was to determine temporal trends in the prevalence of oral manifestations of human immunodeficiency virus (HIV)...
  39. doi request reprint Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline
    M C Hosseinipour
    University of North Carolina Project, Lilongwe, Malawi
    HIV Med 11:510-8. 2010
    ..Advanced disease progression may occur before switching to second-line ART. We report outcomes for patients evaluated and initiated on second-line treatment in Malawi...
  40. ncbi request reprint Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S
    Sonia Napravnik
    Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7215, USA
    AIDS Care 18:S45-50. 2006
    ..Interventions including more intensive counseling and active outreach for newly HIV diagnosed individuals and support with obtaining health insurance and transportation may lead to improved outcomes...
  41. ncbi request reprint Emotional distress in African American women with HIV
    Margaret Shandor Miles
    The University of North Carolina at Chapel Hill, NC, USA
    J Prev Interv Community 33:35-50. 2007
    ..Variables most often affecting various mood states included personal factors (public housing, unemployment, and social conflict) and worry about having HIV worry...
  42. pmc Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir
    Amanda H Corbett
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Antimicrob Agents Chemother 50:2756-61. 2006
    ..67 [0.54 to 0.83] and 0.77 [0.59 to 0.99], respectively) compared to simultaneous administration. Additional investigations are warranted to determine the optimal dosing of FPV with LPV/RTV...
  43. ncbi request reprint Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection
    Thomas D Parsons
    University of North Carolina, Chapel Hill, North Carolina 27599 7025, USA
    AIDS 20:1591-5. 2006
    ..This study examined the effects of HAART on neurocognitive functioning in persons with hepatitis C virus (HCV) and HIV co-infection...
  44. ncbi request reprint Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients
    Sonia Napravnik
    Division of Infectious Diseases, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    AIDS 21:825-34. 2007
    ..HIV-1 triple-class antiretroviral drug resistance (TC-DR) may substantially limit therapeutic options and compromise clinical outcomes...
  45. ncbi request reprint Immunosuppression, hepatitis C infection, and acute renal failure in HIV-infected patients
    Nora Franceschini
    Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC 27514, USA
    J Acquir Immune Defic Syndr 42:368-72. 2006
    ..Low CD4 cell counts predict HIV-related morbidity and mortality and may be associated with acute renal failure (ARF)...
  46. ncbi request reprint Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers
    Rosa F Yeh
    School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA
    J Acquir Immune Defic Syndr 42:52-60. 2006
    ....
  47. ncbi request reprint Frequent detection of acute HIV infection in pregnant women
    Kristine B Patterson
    School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    AIDS 21:2303-8. 2007
    ..Universal prenatal HIV antibody testing, which does not detect acute HIV, is standard for pregnant women in the United States. Unrecognized HIV acquisition during pregnancy may result in higher rates of perinatal transmission...
  48. pmc Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden
    Stephen R Cole
    Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599 7435, USA
    Am J Epidemiol 171:198-205. 2010
    ..Copy-years viremia, a novel measure of cumulative viral burden, may provide prognostic information beyond traditional single measures of viremia...
  49. pmc The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy
    Mina C Hosseinipour
    University of North Carolina Project, Lilongwe, Malawi
    AIDS 23:1127-34. 2009
    ..We evaluated drug resistance patterns among patients failing first-line ART on the basis of clinical or immunological criteria in Lilongwe and Blantyre, Malawi...
  50. pmc Barriers and facilitators to HIV testing and linkage to primary care: narratives of people with advanced HIV in the Southeast
    Sandra I McCoy
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
    AIDS Care 21:1313-20. 2009
    ..Implications for the implementation of Centers for Disease Control and Prevention HIV routine screening guidelines are discussed...
  51. pmc Social support and delays seeking care after HIV diagnosis, North Carolina, 2000-2006
    Sandra I McCoy
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
    AIDS Care 21:1148-56. 2009
    ..The presence of positive social interaction may be an important factor influencing care-seeking behavior after diagnosis...
  52. doi request reprint Severe postvaccinia encephalitis with acute disseminated encephalomyelitis: recovery with early intravenous immunoglobulin, high-dose steroids, and vaccinia immunoglobulin
    Cornelius N Van Dam
    Department of Internal Medicine Infectious Diseases, University of North Carolina Area Health Education Centers Program, Moses Cone Hospital, Greensboro, NC 27401 1020, USA
    Clin Infect Dis 48:e47-9. 2009
    ..Both affected patients responded dramatically with early intervention of intravenous immunoglobulin. Our patient, who also received concurrent vaccinia immunoglobulin and corticosteroids, demonstrated full recovery...
  53. pmc Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay
    Paul Stewart
    The University of North Carolina at Chapel Hill, Department of Biostatistics, Chapel Hill, NC 27599 7420, USA paul
    J Clin Virol 49:198-204. 2010
    ....
  54. pmc Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary HIV care
    Emily Suzanne Brouwer
    Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
    Pharmacoepidemiol Drug Saf 20:432-9. 2011
    ..In this study we assessed the ability of HIV-infected patients receiving care in a university infectious diseases clinic to accurately recall current and past ARVs...
  55. pmc Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population
    Bradley N Gaynes
    Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    Psychosom Med 70:505-11. 2008
    ..Among those persons with psychiatric illness, psychiatric comorbidity (multiple simultaneous diagnoses) is associated with increased psychiatric severity and higher HIV risk behaviors...
  56. pmc Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies
    Kristine B Patterson
    University of North Carolina, Chapel Hill, NC 27599 7215, USA
    Clin Infect Dis 49:473-6. 2009
    ..Changes in CD4 counts or human immunodeficiency virus type 1 RNA levels were similar at 24, 48, and 96 weeks after treatment initiation. ART-naive women should respond to ART regardless of menopausal status...
  57. ncbi request reprint Incidence and etiology of acute renal failure among ambulatory HIV-infected patients
    Nora Franceschini
    Division of Nephrology and Hypertension, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Kidney Int 67:1526-31. 2005
    ..Its incidence and causes have not been studied since the introduction of highly active antiretroviral therapy (HAART) in HIV ambulatory patients...
  58. pmc Acute HIV revisited: new opportunities for treatment and prevention
    Christopher D Pilcher
    Department of Medicine, University of North Carolina at Chapel Hill, 27599 7215, USA
    J Clin Invest 113:937-45. 2004
    ..In this review article, we will highlight critical opportunities for HIV treatment and prevention that are presented by these diagnostic strategies...
  59. ncbi request reprint Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men
    Y Sunila Reddy
    School of Pharmacy, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Infect Dis 186:1339-43. 2002
    ..In SP, EFV reaches concentrations above the HIV-1 IC(90)(WT) throughout the dosing interval. EFV-containing regimens effectively suppress HIV-1 RNA in SP...
  60. ncbi request reprint Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction
    Michael L Lim
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Acquir Immune Defic Syndr 36:1034-40. 2004
    ..LPV/RTV may increase PHT clearance via CYP2C9 induction. Management should be individualized to each patient; dosage or medication adjustments may be necessary...
  61. ncbi request reprint Gender difference in HIV RNA levels: a meta-analysis of published studies
    Sonia Napravnik
    School of Public Health, Department of Epidemiology, Division of Infectious Diseases, University of North Carolina at Chapel Hill, 27599, USA
    J Acquir Immune Defic Syndr 31:11-9. 2002
    ....
  62. ncbi request reprint Perceived oral health status, unmet needs, and barriers to dental care among HIV/AIDS patients in a North Carolina cohort: impacts of race
    Lauren L Patton
    Department of Dental Ecology, CB 7450, School of Dentistry, University of North Carolina, Chapel Hill, NC 27599 7450, USA
    J Public Health Dent 63:86-91. 2003
    ..This prospective observational study examined differences in perceived oral health status, treatment needs, dental care utilization patterns, and barriers to care between HIV-infected non-Hispanic blacks and whites in North Carolina...
  63. ncbi request reprint Brief but efficient: acute HIV infection and the sexual transmission of HIV
    Christopher D Pilcher
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Infect Dis 189:1785-92. 2004
    ..We examined whether viral dynamics in the genital tract during the natural history of acute human immunodeficiency virus type 1 (HIV-1) infection could explain efficient heterosexual transmission of HIV...
  64. ncbi request reprint Detection of acute infections during HIV testing in North Carolina
    Christopher D Pilcher
    Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, USA
    N Engl J Med 352:1873-83. 2005
    ..North Carolina has added nucleic acid amplification testing for the human immunodeficiency virus (HIV) to standard HIV antibody tests to detect persons with acute HIV infection who are viremic but antibody-negative...
  65. ncbi request reprint The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850)
    Arlene S Pereira
    Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
    J Infect Dis 186:198-204. 2002
    ..The antiretroviral effect of APV monotherapy was related to APV concentrations...
  66. ncbi request reprint HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia
    Sonia Napravnik
    School of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, 27599, USA
    J Acquir Immune Defic Syndr 40:34-40. 2005
    ....
  67. ncbi request reprint Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population
    Christopher D Pilcher
    Department of Medicien, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7030, USA
    JAMA 288:216-21. 2002
    ..However, HIV nucleic acid-based testing is widely used to screen for antibody-negative acute infection among low-risk blood donors...
  68. ncbi request reprint Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry
    Arlene S Pereira
    Department of Pathology, School of Medicine, University of North Carolina, Chapel Hill 27599, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 766:307-17. 2002
    ..Recently, this simple and sensitive method was used to determine amprenavir concentrations in seminal samples collected from HIV-1 positive subjects receiving amprenavir antiretroviral therapy as part of a multicenter clinical trial...
  69. pmc Recruitment of HIV/AIDS treatment-naïve patients to clinical trials in the highly active antiretroviral therapy era: influence of gender, sexual orientation and race
    P Menezes
    Division of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
    HIV Med 12:183-91. 2011
    ..We assessed the demographic predictors of trial participation in antiretroviral-naïve patients...
  70. ncbi request reprint Naïve T cells are maintained in the periphery during the first 3 months of acute HIV-1 infection: implications for analysis of thymus function
    Gregory D Sempowski
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Immunol 25:462-72. 2005
    ....
  71. ncbi request reprint Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care
    Dina Hooshyar
    Division of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, North Carolina 27599 7215, USA
    AIDS 20:575-83. 2006
    ..To estimate the effect of hepatitis C (HCV) coinfection on time to first occurrence of either discontinuation or modification of initial HAART among previously antiretroviral therapy-naive HIV-infected patients...
  72. ncbi request reprint Validation of a brief screening instrument for substance abuse and mental illness in HIV-positive patients
    Brian Wells Pence
    Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
    J Acquir Immune Defic Syndr 40:434-44. 2005
    ..Yet SA/MI often go untreated due in part to a lack of practical, validated screening tools...
  73. ncbi request reprint Novel therapies based on mechanisms of HIV-1 cell entry
    J Michael Kilby
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 348:2228-38. 2003
  74. ncbi request reprint Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients
    Rahul P Bakshi
    Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA
    AIDS Res Hum Retroviruses 23:1360-5. 2007
    ..Since a significant reduction in dATP was measurable only when ddI was combined with HU, the antiretroviral activity of ddI may be more complex than previously assumed...
  75. ncbi request reprint Antiretroviral therapy: new drugs, formulations, ideas, and strategies
    Joseph J Eron
    University of North Carolina, Chapel Hill, NC, USA
    Top HIV Med 17:146-50. 2009
    ..Eron, Jr, MD, at the International AIDS Society-USA continuing medical education program in Chicago in May 2009. The original presentation is available as a Webcast at www.iasusa.org...
  76. ncbi request reprint Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings
    Amy C Weintrob
    Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Arch Intern Med 163:2097-100. 2003
    ..Human immunodeficiency virus is infrequently diagnosed during primary infection. More expeditious diagnosis of human immunodeficiency virus infection is a clinical and public health imperative...
  77. pmc Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalization
    William L Ince
    Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, North Carolina 27599 7295, USA
    J Virol 83:4068-80. 2009
    ..Our results suggest that the HIV-1 env subpopulations detectable in the peripheral blood are produced by cells with similar life spans and are not genetically isolated within particular cell types...
  78. ncbi request reprint A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir
    Scott M Hammer
    Columbia University, New York, NY, USA
    Antivir Ther 8:507-18. 2003
  79. ncbi request reprint Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine
    Roy M Gulick
    Weill Medical College of Cornell University, New York, USA
    AIDS 17:2345-9. 2003
    ..To assess virological and immunological responses and toxicity in subjects receiving combination antiretroviral therapy...
  80. ncbi request reprint Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America
    Jacob P Lalezari
    Quest Clinical Research, Mount Zion Hospital and the University of California, San Francisco, San Francisco 94115, USA
    N Engl J Med 348:2175-85. 2003
    ..The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor...
  81. ncbi request reprint A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
    Jacob P Lalezari
    Quest Clinical Research, San Francisco, CA 94115, USA
    AIDS 17:691-8. 2003
    ..Secondary objectives included the determination of enfuvirtide pharmacokinetics and antiviral activity and the immunological response to the enfuvirtide-containing regimen...
  82. ncbi request reprint The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults
    J Michael Kilby
    UAB HIV Outpatient Clinic, University of Alabama at Birmingham, CCB 245A, 908 20th Street South, Birmingham, AL 35294 2050, USA
    AIDS Res Hum Retroviruses 18:685-93. 2002
    ..Injection site reactions were common but generally mild. These results indicate that enfuvirtide is a promising new therapeutic agent for HIV-infected patients, including those with prior antiretroviral treatment...
  83. ncbi request reprint High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    HIV Clin Trials 8:193-204. 2007
    ..To investigate the efficacy and safety of high-dose lopinavir/ritonavir (LPV/r) therapy in multiple protease inhibitor, non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced subjects...
  84. ncbi request reprint Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study
    Charles Hicks
    Duke University Medical Center, Durham, North Carolina, 27710, USA
    AIDS 18:775-9. 2004
    ..Results of long-term therapy with LPV/r-based regimens have not been previously reported. This study describes the 4-year (204-week) safety and antiretroviral activity of LPV/r-based treatment in antiretroviral-naive individuals...
  85. doi request reprint Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
    HIV Clin Trials 9:91-102. 2008
    ....
  86. ncbi request reprint Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Georgia, USA
    AIDS 19:1607-15. 2005
    ..To evaluate the pharmacodynamics and safety of escalating doses of amdoxovir (DAPD) monotherapy administered to treatment-naive and experienced HIV-1-infected patients over 15 days...
  87. ncbi request reprint Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence
    Hulin Wu
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
    J Pharmacokinet Pharmacodyn 33:399-419. 2006
    ..But their combinations in viral dynamic modeling significantly predicted virologic response. The HIV dynamic modeling can appropriately capture complicated nonlinear relationships and interactions among multiple covariates...
  88. ncbi request reprint Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States
    Brian Wells Pence
    Center for Health Policy, Duke University, Durham, NC 27708, USA
    J Acquir Immune Defic Syndr 42:298-306. 2006
    ..Appropriate policy and program planning require accurate prevalence estimates. Yet most estimates are based on screening instruments, which are likely to overstate true prevalence...
  89. ncbi request reprint Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance
    Hulin Wu
    Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Acquir Immune Defic Syndr 39:272-83. 2005
    ..The proposed mathematic models and statistical techniques may provide a framework to simulate and predict antiviral response for individual patients...
  90. ncbi request reprint Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068
    Jeffrey M Jacobson
    Beth Israel Medical Center and Albert Einstein College of Medicine, New York, NY 10003, USA
    J Infect Dis 194:623-32. 2006
    ....
  91. ncbi request reprint Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy
    Brian Wells Pence
    Center for Health Policy, Duke University, Durham, NC 27708 0253, USA
    J Acquir Immune Defic Syndr 44:159-66. 2007
    ..MI/SA consistently predict poorer antiretroviral adherence, suggesting that affected patients should be at higher risk of poor virologic and immunologic response to highly active antiretroviral therapy (HAART)...
  92. ncbi request reprint A brief mental health and substance abuse screener for persons with HIV
    Kathryn Whetten
    Health Inequalities Program, Duke University, Durham, NC 27708, USA
    AIDS Patient Care STDS 19:89-99. 2005
    ..The screener is not a diagnostic instrument and has limited value in predicting specific psychiatric diagnoses...
  93. ncbi request reprint Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307
    Ian Frank
    AIDS Res Hum Retroviruses 20:916-26. 2004
    ..HU may continue to have a role as a component of HIV therapy...
  94. ncbi request reprint 14th annual retrovirus conference (CROI). One-on-one with Joseph J. Eron, MD. Interview by Jeff Berry
    Joseph J Eron
    Posit Aware 18:31-3. 2007
  95. ncbi request reprint The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine
    Joseph J Eron
    J Acquir Immune Defic Syndr 45:249-51. 2007
  96. ncbi request reprint TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals
    Jacques Reynes
    Hopital Gui de Chauliac, CHU Montpellier, France
    AIDS Patient Care STDS 21:533-43. 2007
    ..In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial...
  97. ncbi request reprint Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy
    Jeff D Moore
    University of Alabama at Birmingham, Division of Clinical Pharmacology, Birmingham, AL, USA
    Antivir Ther 12:981-6. 2007
    ..Little is known about how commonly used dual-NRTI regimens affect the intracellular levels of NRTI-TPs, the active form of these drugs. This study investigates the effect of dual-NRTI therapy in intracellular NRTI-TP levels...
  98. ncbi request reprint Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals
    Edward P Acosta
    Division of Clinical Pharmacology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 0019, USA
    J Acquir Immune Defic Syndr 37:1358-66. 2004
    ....
  99. ncbi request reprint Simplifying antiretroviral therapy
    Michael L Tapper
    New York University School of Medicine, New York, USA
    AIDS Read 14:355-60, 367-71. 2004
    ..Additional studies should add to this experience and provide guidance on the role and timing of such regimens in the management of patients with HIV disease...
  100. doi request reprint Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients
    Robert L Murphy
    Northwestern University, Chicago, Illinois, USA
    HIV Clin Trials 9:1-10. 2008
    ..Evaluate efficacy and tolerability of lopinavir/ritonavir (LPV/r) plus stavudine and lamivudine long term in antiretroviral-naïve patients...
  101. pmc Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience
    Lisa M Demeter
    University of Rochester, Rochester, New York 14642, USA
    HIV Clin Trials 9:11-25. 2008
    ..EFV+IDV plus abacavir (ABC) in 283 nucleoside-experienced HIV-infected patients...

Research Grants3

  1. University of North Carolina AIDS Clinical Trials Unit (UNC ACTU)
    Joseph Eron; Fiscal Year: 2007
    ..The UNC CTU and its four Clinical Research Sites will improve the treatment of HIV and decrease HIV spread by contributing to HIV prevention strategies and HIV vaccine development. ADMINISTRATIVE COMPONENT: ..